Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
9.00
+0.04 (0.45%)
Aug 13, 2026, 4:00 PM EDT - Market closed
Vir Biotechnology Revenue
Vir Biotechnology had revenue of $238.95M in the quarter ending June 30, 2026, with 19,582.54% growth. This brings the company's revenue in the last twelve months to $303.23M, up 1,495.93% year-over-year. In the year 2025, Vir Biotechnology had annual revenue of $68.56M, down -7.61%.
Revenue (ttm)
$303.23M
Revenue Growth
+1,495.93%
P/S Ratio
5.02
Revenue / Employee
$826,232
Employees
367
Market Cap
1.52B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 68.56M | -5.65M | -7.61% |
| Dec 31, 2024 | 74.21M | -11.98M | -13.90% |
| Dec 31, 2023 | 86.18M | -1.53B | -94.67% |
| Dec 31, 2022 | 1.62B | 520.38M | 47.51% |
| Dec 31, 2021 | 1.10B | 1.02B | 1,334.39% |
| Dec 31, 2020 | 76.37M | 68.28M | 843.86% |
| Dec 31, 2019 | 8.09M | -2.58M | -24.16% |
| Dec 31, 2018 | 10.67M | 7.96M | 293.94% |
| Dec 31, 2017 | 2.71M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
VIR News
- 7 days ago - Vir Biotechnology price target lowered to $25 from $27 at Morgan Stanley - TheFly
- 7 days ago - Vir Biotechnology price target lowered to $19 from $21 at Leerink - TheFly
- 8 days ago - Vir Biotechnology reports Q2 EPS 47c vs. (80c) last year - TheFly
- 8 days ago - Vir Biotechnology Earnings Call Transcript: Q2 2026 - Transcripts
- 8 days ago - Vir Biotechnology Slides: Q2 2026 - Filings
- 8 days ago - Vir Biotechnology Earnings release: Q2 2026 - Filings
- 8 days ago - Vir Biotechnology Quarterly report: Q2 2026 - Filings
- 8 days ago - Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Business Wire